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Abstract
The transcription factor sterol regulatory element binding protein (SREBP)-1a plays a pivotal role in lipid metabolism. Using
the SREBP-1a expressing human hepatoma cell line HepG2 we have shown previously that human SREBP-1a is
phosphorylated at serine 117 by ERK-mitogen-activated protein kinases (MAPK). Using a combination of cell biology and
protein chemistry approach we show that SREBP-1a is also target of other MAPK-families, i.e. c-JUN N-terminal protein
kinases (JNK) or p38 stress activated MAP kinases. Serine 117 is also the major phosphorylation site in SREBP-1a for JNK. In
contrast to that the major phosphorylation sites of p38 MAPK family are serine 63 and threonine 426. Functional analyses
reveal that phosphorylation of SREBP-1a does not alter protein/DNA interaction. The identified phosphorylation sites are
specific for both kinase families also in cellular context. To provide direct evidence that phosphorylation of SREBP-1a is a
regulatory principle of biological and clinical relevance, we generated transgenic mice expressing mature transcriptionally
active N-terminal domain of human SREBP–1a variant lacking all identified phosphorylaton sites designed as alb-SREBP-
1aDP and wild type SREBP-1a designed as alb-SREBP-1a liver specific under control of the albumin promoter and a liver
specific enhancer. In contrast to alb-SREBP–1a mice the phosphorylation–deficient mice develop no enlarged fatty livers
under normocaloric conditions. Phenotypical examination reveales a massive accumulation of adipose tissue in alb-SREBP-
1a but not in the phosphorylation deficient alb-SREBP-1aDP mice. Moreover, preventing phosphorylation of SREBP-1a
protects mice also from dyslipidemia. In conclusion, phosphorylation of SREBP-1a by ERK, JNK and p38 MAPK-families
resembles a biological principle and plays a significant role, in vivo.
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Introduction
Sterol regulatory element binding proteins (SREBPs) are the
predominant transcription factors controlling the synthesis of
cholesterol and fatty acids in liver [1]. The family of SREBPs
encompasses essentially two isoforms, SREBP–1 and SREBP–2,
encoded by the corresponding genes SREBF-1 and SREBF-2
[2,3]. In contrast to SREBF–2, SREBF–1 is transcribed into two
major splice variants, SREBP-1a and SREBP-1c, differing in the
first exon of the mature protein [2,3]. Several lines of evidence
indicate that SREBP–2 is the master regulator of cholesterol
synthesis, whereas the isoform SREBP–1c controls the synthesis of
fatty acids and is unique in the SREBP family in the regulation of
lipogenesis by carbohydrates. However, the isoform SREBP–1a
can control both pathways of lipid synthesis to a main degree [1,3–
9]. The different functions for the SREBP-1 isoforms are mainly
thought to be casued by the different length of the N-terminal
transactivation domain. Whereas this domain of SREBP-2 and
SREBP-1a has a comparable length the respective N-Terminal
domain of SREBP-1c is much shorter and a much weaker
transcriptional activator. [10]. So SREBP-1a, -1c and-2 may have
different specifics to the members of the family of binding and
integrator proteins. Whereas SREBP-1a and -2 is active to a
similar degree on genes with a promoter with the classical sre-1-
element SREBP-1c is not. On the other hand SREBP-1a and
SREBP-1c act comparable on genes with a promoter containing
E-box element, but not SREBP-2 [8,9,11,12].
Furthermore the SREBP-1 isoforms differ in the expresson
levels, e.g. transcripts of SREBP-1c are approximately 10 fold
higher abundant in liver as SREBP-1a [3,13]. SREBP-1c is
thought to be a basal transcription factor and SREBP-1a that has a
much stronger transactivation activity is thought to be responsible
for regulation upon physiological demands [5].
One essential feature of SREBPs is that they are transcribed and
translated into inactive precursor molecules which are embedded
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composition of this pool still remains unclear and an accumulation
of either SREBP isoform, even if the expression rates are reduced
cannot be excluded. To generate the transcriptional active
domain, SREBPs are released by a complex two-step sequential
proteolytic machinery initiated by cholesterol depletion of the cell.
Only the mature forms of SREBPs translocate in the nucleus and
activate target genes [14]. Beside proteolytic cleavage, which
controls the abundance the transcriptional activity of SREBP-1a
can be directly modified by phosphorylation and we have
demonstrated that trans-activity of the mature N-terminal domain
of SREBPs is regulated directly by extra cellular stimuli, e.g. by
hormones such as insulin [15–20]. Moreover, in these studies, we
have shown that the N-terminal domains of SREBP-1a, SREBP-
1c, and SREBP-2 are direct substrates of the extracellular signal-
regulated kinase (ERK) subfamily of mitogen-activated protein
kinases (MAPK). This mechanism might place SREBP-1a as a
gene regulatory point of convergence for inflammation, insulin
resistance, obesity and intracellular lipid accumulation, since
hormones, cytokines, drugs, and free fatty acids are able to activate
SREBPs via MAPK cascades [18].
It is well known that other MAPK cascades, like JNK (c-JUN N-
terminal protein kinase) as well as p38 MAP kinases, target
transcription factors directly by phosphorylation, thereby altering
their transactivity, leading to changes of cellular gene regulatory
networks [21]. However, it is still unclear whether these MAP
kinases, which are triggered by inflammatory and stress signals
including cytokines can also regulate directly intracellular lipid
homeostasis. This could be a missing link between inflammation
and alterations in lipid accumulation, which are also frequently
associated with insulin resistance, obesity, and an increased
cardiovascular risk.
Since SREBP-1a is the master regulator of both pathways, i.e.
synthesis of fatty acids as well as cholesterol, we had the
hypothesis, that SREBP-1a is phosphorylated by JNK and p38
MAPK thereby altering transcriptional activity and cellular lipid
metabolism. Accordingly in this report we show, that SREBP–1a is
directly phosphorylated by members of stress kinases families, i.e
JNK and p38 MAPK. Using protein chemistry methodology we
identify the major kinase specific phosphorylation. In HepG2 cells
we have shown, that identified phosphorylation sites are also
targets in cellular context. Furthermore, to study physiological and
clinical impact of SREBP-1a phosphorylation, we generated
mouse models that overexpress the transcriptional active wild
type domain of SREBP-1a or a construct in which all identifed
MAPK phosphorylation were destroyed by mutation in liver.
Using these transgenic mouse models we provide first evidence
that phosphorylation of SREBP–1a at these site appears to be of
physiological relevance.
Results
Identification of stress activated MAP kinases specific
phosphorylation sites in SREBP-1a
Previously we have shown that the N-terminal domain of
human SREBP-1a is a substrate for ERK kinase and identified
S117 as the major phosphorylation site [16]. Here we investigated
if SREBP-1a is also substrate of JNK and p38 MAPK families. To
identify the major related phosphorylation sites in we incubated
the N-terminal domain of SREBP-1a (SREBP-1a-NT) as purified
recombinant GST fusion protein with activated purified recom-
binant JNK1 and JNK2 or p38a, ß and c (Figure 1A). The results
showed that SREBP-1a-NT was also an efficient substrate for all
kinases with an average of 0.9 mole phosphates per mole protein
for JNK isoforms and 1.5 mole phosphates per mole protein for
the p38 isoforms. To test whether major ERK site S117A is also
the target of JNK or p38, the S117A mutant of GST-SREBP-1a-
NT was phosphorylated by JNK1, JNK2 or p38a, ß and c. The
phosphorylation efficiency of JNK1 or JNK2 on SREBP-1a
S117A was reduced by 90%, whereas phosphorylation by the p38
kinase isoforms were not altered compared to wild type (Figure 1A).
This indicates that JNK1 and 2 but not p38 phosphorylate SREBP
at position S117. Anion exchange HPLC maps of trypsin-digested
SREBP-1a-NT GST fusion proteins phosphorylated by JNK show
one predominant peak that was abolished in the profile performed
with GST-SREBP-1a-NT S117A (see Fig. 1B) confirming S117 as
the major phosphorylation site for JNK in SREBP-1a.
The profile of SREBP-1a-NT phosphorylated by p38 was
completely different and more complex (Figure 1C). Using the
GST-SREBP-1a-NT wild type and S117A revealed similar
patterns. The results showed that SREBP-1a was very efficiently
phosphorylated by all p38 kinases but the identified major
phosphorylation site for ERK and JNK, namely S117, was not
the target of p38 phosphorylation in SREBP-1a.
In order to identify the major p38 MAP kinases specific
phosphorylation sites in SREBP-1a we analyzed in vitro phosphor-
ylated radiolabelled GST-SREBP-1a-NT by reversed phase mass
spectrometry. The radiolabelled peak 1 phosphopeptide detected
in an UV elution profile (Figure 2 A) was identified as human
SREBP-1 aa 419–446 in which T426 was phosphorylated by mass
spectrometry (Figure 2B) whereas peak 2 and peak 3 could not be
assigned directly. Edman degradation assays identified peak 2 and
peak 3 as identical peptides representing the N-terminal part of
mature SREBP-1a (aa 1–108). This peptide contains three typical
consensus sequences for MAPK (PXS/TP) phosphorylation sites
i.e. S63, S98 and T105. GST fusion proteins containing the
corresponding mutants i.e. S63A, S98A and T105V were analyzed
by in vitro phosphorylation assays (Figure 2C) and by anion
exchange HPLC of the trypsin-digested proteins (Figure 2D).
Compared to wild type SREBP-1a (Figure 2B) the first peak of
SREBP-1a-NT profile is lost by S63A, whereas neither S98A nor
T105A altered the elution profiles (Figure 2D). This provided
strong evidence that S63 is a second major phosphorylation site for
p38 in SREBP-1a beside T426.
MAPK p38a in vitro phosphorylation assay using single mutants
SREBP-1a-NT S63A and SREBP-1a-NT T426V as well as the
double mutant, i.e. SREBP-1a-NT S63A/T426V supported the
findings. Compared to wild type SREBP-1a-NT phosphate
incorporation was reduced by approximately 60% for each single
mutation and approximately 80% in the double mutant S63A/
T426V (Figure 3A). This was confirmed by anion exchange
chromatography of each p38a phosphorylated trypsin-digested
SREBP-1a-NT. Each single mutant and the double mutant S63A/
T426V were lacking any significant radioactive fraction
(Figure 3B). Thus, we conclude that S63 and T426 are the
predominant phosphorylation sites of p38a in SREBP-1a.
Phosphorylation assays of SREBP-1a-NT or mutated SREBP-
1a-NT (S63A, T426V and S63A/T426V) using p38b or p38c
(Figure 3C) revealed that S63 and T426 were not a specific feature
of p38a isoform rather than the p38 family. The reduction of
phosphate incorporation in the mutated proteins was comparable
to the reduction obtained with p38a (compare Figure 3C with
Figure 3A).
JNK and p38 MAPK phosphorylation of SREBP-1a did not
intefere with protein/DNA interaction
Phosphorylation can influence protein/DNA interaction.
Therefore we used in vitro transcribed and translated His-
Phosphorylation of SREBP-1a by JNK and p38 Kinases
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e32609Figure 1. Identification of S117 as major JNK related phosphorylation site in SREBP-1a. (A)1 0mg GST-SREBP-1a-NT and GST-SREBP-1a-NT
S117A were phosphorylated by activated recombinant JNK1 or JNK2 (40 ng/mg protein) or recombinant p38 isoforms p38a, p38b, p38c (40 ng/mg
protein) in vitro and separated by 10% SDS-PAGE. A coomassie blue stained gel (left), autoradiography of SDS-PAGE of JNK1, JNK2, p38a, p38b or
p38c phosphorylation is shown. The arrow marks band of SREBP-1a. The excised radioactive slices of GST-SREBP-1a-NT or GST-SREBP-1a-NT S117A
phosphorylated by JNK1 (B) or phosphorylated by p38a (C) were digested by trypsin and the resulting peptides were subjected to anion exchange
chromatography. The graph shows the elution fraction plotted against the incorporated radioactivity. Reactions performed are described under
‘‘Materials and Methods’’.
doi:10.1371/journal.pone.0032609.g001
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phosphorylation on protein/DNA interaction. We incubated in
vitro transcribed and translated His-SREBP-1a-NT without or with
JNK1 or p38a and subsequently analyzed the protein/DNA
interaction by EMSA (Figure 4A, B). SREBP-1a-NT interacted
with sre-1 as well as E-box motif to a similar degree.
Phosphorylation of SREBP-1a-NT affected protein/DNA inter-
action neither by JNK1, nor by p38a. This is in accordance to the
observation that ERK phosphorylation of SREBP-1a at S117 does
not influence protein/DNA interaction [16].
JNK and p38 MAPK target the identified phosphorylation
sites of SREBP-1a in intact cells
To test the relevance of identified phoshorylation sites for JNK
as well as p38 MAPK more specificily in cellular context we
performed promoter reporter gene assays recruiting the heterol-
ogous Gal4-system and specific kinases for the MAP kinases
cascades (Figure 5). In this assay, SREBP-1a-NT and the mutated
forms were expressed as fusion proteins with the DNA binding
domain of yeast Gal4 (aa 1–147). The latter domain alone doesn’t
have any trans-activity per se. Accordingly, activities detected
reflect trans-activities of SREBP-1a-NT or its mutants fused to the
yeast Gal4 domain. To activate JNK and p38 signalling selectively
in Hep G2 cells, the constitutively active upstream activators for
JNK, i.e. MKK4DE, or p38, i.e. MKK3DE, were used. To
monitor the specific initiation of JNK and p38 signaling to
SREBP-1a in HepG2 cells MKK4DE or MKK3DE were
cotransfected with wildtype pFA SREBP 1a NT or respective
phosphorylation site mutants. Basal trans-activities of all mutated
forms of SREBP-1a-NT were comparable to wildtype. Constitu-
tive active MKK4DE or MKK3DE synergistically elevated trans-
activity of SREBP-1a-NT by about 3-fold. Transfection of
activated MKK3 or MKK4 showed that S117A specifically
interferes with MKK4 signaling, whereas S63A and T426V
abolished MKK3 signaling. Accordingly the triple mutant
(SREBP-1a-NT S63A/S117A/T426A) failed to be activated by
both kinase pathways. These results clearly show that SREBP-1a
was a specific target for JNK and p38 activation, since the specific
upstream kinases trigger kinase signaling to the specificpho-
sphorylation sites.
Relevance of SREBP-1a phosphorylation in vivo
To investigate the biological relevance of MAPK related
phosphorylation of human SREBP 1a in vivo, we generated
transgenic mice which express selectively in liver the mutant
variant of human SREBP-1a lacking all identified major
phosphorylation sites, designated as SREBP-1aDP (Fig. 6A). In
addition we generated transgenic mice which express liver
specifically the wild type of human SREBP-1a to a similar degree.
Our intent was to study the role of SREBP 1a phosphorylation in
liver for the phenotype of mice. Taken into consideration the
complex and highly regulated releasing cascade of mature
SREBP-1a protein from ER anchoured precursor proteins and
to circumvent secondary cholesterol feedback effects [4] we used
the N–terminal transcriptional active domain. To facilitate
detection a HA-tag was added and for liver specific expression
the albumin promotor and a liver specific enhancer was chosen.
The HA-tag did not affect phosphorylation, trans-activation or
protein/DNA interaction of the N–terminal transcriptional active
domain of SREBP-1a in vitro (data not shown). The mice were bred
on C57Bl6 background which also served as global controls
throughout the study. Viability, fertility or breeding efficiency and
nesting behaviour of the transgenic animals was not affected and
the observed life span was not reduced.
The presence of the transgenes was monitored by genotyping of
the intersection of albumin promoter and SREBP-1a coding
sequence (Figure 6B). As mouse strains might have different
expression levels of the transgenes due to physical integration of
the construct in the genome, we decided to follow strains per
genotype whose expression of transgene had a similar degree
(Figure 6C). In our SREBP-1a overexpressing mouse models the
expression of the differential spliced SREBP-1a isoform SREBP-1c
or SREBP-2 was not altered (Figure 6C). Moreover the expression
of endogenous SREBP-1a determined with mouse specific primers
and probe was not altered in the transgenic mice, too (Figure 6C).
Western blot analyses (Figure 6D) of liver extracts for SREBP-1
protein indicate no alteration in the SREBP-1 precursor protein
fraction in SREBP-1aDP, SREBP-1a and C57Bl6 mice. The total
contend of nuclear SREBP-1 in liver extracts shown in western
blot analyses with an SREBP-1 specific antibody detecting human
and mouse SREBP-1 is increased in the transgenes compared to
C57Bl6. Using HA-tag specific antibody revealed the expression of
the respective transgenes at the protein level to the same degree,
too (Figure 6D, 6E). Western blot analyses with extracts of liver,
pancreas, heart, kidney, small intestine or skeletal muscle tissue
proved that transgenes are expressed solely in liver of alb-SREBP-
1aDP (Figure 6F) or alb-SREBP-1a (Figure 6G) animals.
To determine the functionality of the liverspecific overexpres-
sion of the human transcriptional active domain of SREBP-1a and
the impact of SREBP-1aDP the gene expression of key metabolic
enzymes was analyzed in liver of these animals (Table 1) as a
functional proof of principle. The expression rates of genes
involved in lipid metabolism like FAS, SCD or GPAT and the rate
limiting gene in cholesterol metabolism, HMG-CoAR were at
least doubled in alb-SREBP-1 aDP mice compared to C57Bl6 but
increased more than 10 fold in alb-SREBP-1a mice compared to
C57BL6 mice. Genes involved in lipid transport as LDLR or
ABCA1 were increased 2.5-fold in alb-SREBP-1 aDP mice and
increased more than five- fold in alb-SREBP-1a mice. Interstingly
Figure 2. Identification of p38 specific phosphorylation sites in SREBP-1a-NT. (A) 500 mg GST-SREBP-1a-NT were phosphorylated by p38a
(40 ng/mg protein). Following 10% SDS-PAGE and in-gel trypsin digestion of phosphorylated SREBP-1a-NT, the resulting peptides were fractionated
by reverse-phase HPLC on a C18 column. Peptides were eluted with a 0–95% linear gradient of acetonitrile in 0.1% trifluoroacetic acid. The eluate was
monitored by UV absorbance at 215 nm. Radioactive fractions are marked with asterisks. (B) The HPLC fraction 1, containing radiolabeled peptide,
was analyzed by MALDI-MS in the linear positive-ion mode and lead to identification of a (M+H)
+ peptide having a m/z of 2952.35 Da. MALDI-PSD
analyses using this peptide ion as mass parent ion. Fragmentation mass spectrum of (M+H)
+ peptide with identified internal b- and y-fragment ions
are designated. The interpretation of PSD fragment data allowed identification of the above-designated peptide (TEVEDTLT
*PPPS-
DAGSPFQSSPLSLGSR) (aa 419–446) with phosphorylated T426. (C)1 0mg GST-SREBP-1a-NT and GST-SREBP-1a-NT S63A, GST-SREBP-1a-NT S98A or
GST-SREBP-1a-NT T105V were phosphorylated by activated recombinant p38 isoforms p38a, p38b, p38c (40 ng/mg protein) in vitro and separated by
10% SDS-PAGE. A coomassie blue stained gel (left-hand side) and an autoradiography (right-hand side) of SDS-PAGE of p38a, p38b or p38c
phosphorylation are shown. The arrow marks the band of SREBP-1a. (D) The excised radioactive slices of GST-SREBP-1a-NT, GST-SREBP-1a-NT S63A,
GST-SREBP-1a-NT S98A, or GST-SREBP-1a-NT T105V phosphorylated by p38a were digested by trypsin and the resulting peptides were subjected to
anion exchange chromatography. The graph shows the elution fraction plotted against the incorporated radioactivity. Reactions performed are
described under ‘‘Materials and Methods’’.
doi:10.1371/journal.pone.0032609.g002
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aDP but significantly increased in alb-SREBP-1 a mice. In
SREBP-1 aDP PEPCK expression was elevated six-fold compared
to a fifteen-fold increase in alb-SREBP-1 a mice. There was an
approximately doubling of GLUT-2 expression in alb-SREBP-1a
mice whereas the increase in alb-SREBP-1aDP was not signifi-
cantly altered to C57Bl6. Rate limiting metabolic genes as liver
specific pyruvate kinase or malic enzyme expression were
significantly increased in alb-SREBP-1aDP compared to C57Bl6
but this again does not reach the increase observed in alb-SREBP-
1a animals. Taken together compared to C57Bl6 the effect of the
phosphorylation deficient SREBP-1aDP is a clear inducibility of
gene expression but the effect is by far not as pronounced as in the
wildtype alb-SREBP-1a mice. Furhtermore for all genes investi-
gated a significant increase of expression can be obtained also to
SREBP-1aDP mice.
Mutation of phosphorylation sites in SREBP-1a prevents
excessive weight gain under normocaloric conditions
Transgenic male alb-SREBP-1aDP and alb-SREBP-1a as well
as control C57Bl6 mice were kept in groups of four under
standardized conditions starting with normocaloric standard diet
after weaning at the age of 6 weeks for an observation period of
further 18 weeks. Monitoring the weight gain revealed that
Figure 3. Verification of p38 specific phosphorylation sites in SREBP-1a-NT. (A) Coomassie brilliant blue stained SDS-PAGE of GST-SREBP-
1a-NT and each of mutated SREBP-1a-NT phosphorylated by activated recombinant p38a (40 ng/mg protein). (B) Autoradiography of SDS-PAGE of
GST-SREBP-1a-NT fusion protein, single mutated forms S63A, T426V or double mutant GST-SREBP-1a-NT S63A/T426V phosphorylated by activated
recombinant p38a. Excised radioactive slices of p38a phosphorylated recombinant proteins were trypsin-digested and the resulting peptides GST-
SREBP-1a-NT, S63A, T426V or double mutant S63A/T426V, as indicated in the figure, were subjected to anion exchange chromatography. Elution was
performed with a KH2PO4 pH 4 buffer gradient. Reactions performed are described under ‘‘Materials and Methods’’. (C) Autoradiography of SDS-
PAGE of GST-SREBP-1a-NT fusion protein, single mutated forms S63A, T426V or double mutant GST-SREBP-1a-NT S63A/T426V phosphorylated by
activated recombinant p38b or p38c (40 ng/mg protein).
doi:10.1371/journal.pone.0032609.g003
Figure 4. Effect of phosphorylation on DNA binding and acitvity of SREBP-1a in vitro. (A) His-SREBP-1a-NT fusion protein was incubated
with or without JNK1 (40 ng/mg protein) as indicated. An EMSA of His-SREBP-1a-NT incubated with sre-1 fragment (upper panel) or E-box fragment
(lower panel) is shown. To confirm equal loading, western-blot analyses with monoclonal anti-HisG-HRP antibody was performed. To control
phosphorylation efficiency a JNK1 kinase assay with (c
32P) ATP was performed and dried SDS-PAGE was exposed to X-ray film. For further details see
‘‘Materials and Methods’’. (B) His-SREBP-1a-NT fusion protein was incubated with or without p38a (40 ng/mg protein) as indicated. An EMSA of His-
SREBP-1a-NT incubated with sre-1 fragment (upper panel)or E-box fragment (lower panel) is shown. To confirm equal loading, western-blot analysis
with monoclonal anti-HisG-HRP antibody were performed. To control phosphorylation efficiency a p38a kinase assay with (c
32P) ATP was performed
and dried SDS-PAGE was exposed to X-ray film. For further details see ‘‘Materials and Methods’’.
doi:10.1371/journal.pone.0032609.g004
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to the 15
th week (Figure 7A). Initially alb-SREBP-1aDP mice were
approximately 10% smaller than C57Bl6 and had a weight gain of
only 30% of C57Bl6 mice with a parallel growth curve. At the age
of 6 weeks the alb-SREBP-1a mice were comparable to C57Bl6
mice, but the weight gain of alb-SREBP-1a mice persists
continously. A post-study observation at age of 30 week indicated
their maximum of weight gain with a mean weight of 40 g (data
not shown).
Food intake of C57Bl6 and alb-SREBP-1a mice was not
different whereas alb-SREBP-1aDP mice consumed approximate-
ly 20% less (Figure 7B). At 24 weeks body weight of alb-SREBP-
1aDP mice was like C57Bl6 wereas alb-SREBP-1a were
significantly higher (Figure 7C). This was also observed for liver
weight and white adipose tissue (Figure 7D, E). The ammount of
white adipose tissue per body weight was nearly doubled in alb-
SREBP-1a whereas again alb-SREBP-1aDP and C57 were
identical (Figure 7F). In relation to body weight food uptake was
comparable in both models and controls (Figure 7G). In contrast,
weight gain per food intake disclosed that the amount of food
consumed by alb-SREBP-1aDP was significantly higher than
C57Bl6. More impressively this was calculated for alb-SREBP-1a
mice (Figure 7H). Taken together, preventing phophorylation of
the overexpressed transgene SREBP-1a by mutation of the
phosphorylation sites resulted in reduced weight gain per food
consumed compared to overexpression of the functional wild-type
SREBP-1a.
Preventing phosphorylation of SREBP-1a protects from
fatty liver
Macroscopic liver examination of transgenic and control mice
at the age of 24 weeks revealed that the appearance of alb-SREBP-
1aDP livers were slightly enlarged, but in alb-SREBP-1a mice the
mean liver size were raised about 25% and colouring was slightly
pale (Figure 8A). For further morphological analyses tissues of the
Lobus caudatus, Lobus sinister or dexter lateralis were taken
(Figure 8B). In C57Bl6 and alb-SREBP-1aDP morphological
intact parenchym with dense cytoplasm, clear nucleus, eosino-
philic nucleii and basophile euchromatin can be observed. In
contrast in alb-SREBP-1a mice the general impression of the liver
tissue of was more dimorph, cytoplasma was less dense with more
vacuoles and enlarged cell volume. C57Bl6 and alb-SREBP-1aDP
show similar glycogen granula with slightly perilobular concen-
tration. Glycogen content in alb-SREBP-1a mice was higher and
mainly centered arround the lobus. In some cells it presents as
granula or not related to distinct structures of the cytosol. In alb-
SREBP-1aDP mice accumulation of visible lipid droplets mainly
located around the nucleus was slightly higher than in C57Bl6
mice. Contrary, alb-SREBP-1a mice showed strong lipid accu-
mulation centered around the portal vein spanning whole areas of
the cytosol. In cells with highest ectopic lipid accumulation yet no
signs of cytotoxicity, i.e. degradation of the nuclear structures,
were observed. No gross alterations of connective tissue, collagene
fibers or fibrocytes were detected in C57Bl6 and alb-SREBP-1aDP
mice indicating no signs for fibrosis. In alb-SREBP-1a mice the
matrix was also without any specific alterations. In all cases no Ito
cells, infiltrating monocytes or other inflammation markers were
detected.
Preventing phosphorylation of SREBP-1a protects from
visceral obesity
Macroscopic examination of mice at the age of 24 weeks
revealed that the phenotype of alb-SREBP-1aDP mice was similar
to C57Bl6 mice (Figure 9A). In contrast to that, in alb-SREBP-1a
mice the epididymale and inguinal fat mass was massively
increased leading to a ‘‘potato-shaped’’ appearance of the animals.
In phosphorylation deficient alb-SREBP-1aDP mice no excess fat
mass could be determined. Histological sections of the adipose
tissue revealed adipocyte hyperplasie but no hypertropy and also
no signs of macrophage infiltration (Figure 9B). So, SREBP-1a
specifically expressed in liver results not only in the development of
enlarged fatty livers but also has a massive impact on whole body
fat mass. This alteration of body composition was abolished by
preventing SREBP-1a from phosphorylation.
Systemic influence of SREBP-1a phosphorylation
As expected from the macroscopic examination determination
of body weight, liver weight, and weight of visceral fat indicated
that alb-SREBP-1a animals had significantly increased values of
serum parameters including dyslipidemia and insulin resistance,
whereas the alb-SREBP-1aDP mice were more comparable to
wildtype C57Bl6 (Table 2). Triglyceride levels but not serum
cholesterol were massively increased in alb-SREBP-1a mice
whereas the phosphorylation deficient alb-SREBP-1aDP showed
a slightly reduced TG level as C57Bl6 mice. Free fatty acid (FFA)
levels in serum showed that in alb-SREBP-1aDP mice an elevation
by 50% compared to C57BL6 can be determined and alb-SREBP-
Figure 5. Effect of phosphorylation on DNA binding and
acitvity of SREBP-1a. HepG2 cells were transiently transfected with
pG5-luc (0.5 mg/well) and pFA-SREBP-1a-NT or the mutants S117A,
S63A/T426V, S63A/S117A/T426V (25 ng/well) in the presence 25 ng/
well MKK3DE and MKK4DE, respectively as indicated. Cells were
maintained for 16 h before harvesting and analyses of dual luciferase
activity. Transfection efficiency was controlled by co-transfection of
pRL(-mcs)-vector (0.1 mg/well). Promoter strength of the LDL receptor
gene is represented by the relative luciferase activities. Results are given
as means (6S.D.) of five independent experiments, each performed in
triplicate (p,0.01).
doi:10.1371/journal.pone.0032609.g005
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to this only the alb-SREBP-1a mice had significantly elevated liver
function tests, i.e. GPT/ALT and GOT/AST, respectively. Leptin
levels were elevated only in alb-SREBP-1a mice in accordance to
the increased fat mass. Blood glucose and insulin were increased in
alb-SREBP-1a mice, whereas in alb-SREBP-1aDP mice soley
insulin was modestly elevated.
As expected the content of total fatty acid (TFA) in liver of alb-
SREBP-1a mice was approximately fourfold higher as in liver of
C57Bl6 mice. In contrast the phosphorylation deficient mice were
mostly protected against lipid accumulation and show a 1.5 fold-
increase. Detailed analyses of fatty acid composition in liver tissues
and serum were performed (Figure 10). In liver the content of
saturated FA, i.e. C16:0 was unaltered and C18:0 was slightly
reduced in phosphorylation deficient mice alb-SREBP-1aDP but
massively reduced alb-SREBP1a mice in comparison to C57Bl6.
The level of mono unsaturated FA C16:1 was increased three fold
in alb-SREBP-1aDP and four fold alb-SREBP-1a mice. C18:1
showed an 1.5 fold- increase in alb-SREBP-1aDP and a 2.5 fold-
increase alb-SREBP-1a mice. Polyunsaturated fatty acids C18:2,
C18:3 and C20:4 contend showed a genotypespecific reduction in
the transgenic mouse models which was most prominent in alb-
SREBP-1a mice whereas alb-SREBP-1aDP mice were more
comparable to C57Bl6. Compared to the levels determined for
C57Bl6, there is a pronounced increase in C16:1 and C18:1 for
alb-SREBP-1aDP that is further doubled in alb-SREBP-1a mice.
Also the reduced levels for the further FA observed in alb-SREBP-
1aDP were nearly doubled in alb-SREBP-1a mice (Figure 10A). In
serum the FFA pattern of mice is essentially comparable to liver,
but the differences are not that pronounced. Also the differences in
relation to C57Bl6 when significant, again show a pattern with the
largest differences observed for alb-SREBP-1a mice and the alb-
SREBP-1aDP beeing intermediate to C57BL6 and alb-SREBP-1a
mice (Figure 10B).
Phosphorylation of SREBP-1a influences insulin sensitivity
The mice overexpressing functional SREBP-1a in liver
developed a fatty liver, but the phenotype is abrogated if the
main phosphorylation sites in SREBP-1a were mutated as in alb-
SREBP-1aDP mice. Excess intracellular lipid accumulation in
hepatocytes impairs liver functionality and insulin sensitivity.
Caculating of HOMA-IR index as surogate for insulin resistance
indicated that alb-SREBP 1aDP mice have a comparable level to
C57Bl6, but the variation within this genotype is broarder. The
HOMA-IR index of the alb-SREBP 1a mice indicated the
beginning of insulin resistance. QUICKI as surogate for insulin
sensitivity indicated for alb-SREBP 1aDP that the insulin
sensitivity was in normal range but with larger varaition that the
controls. In contrast for alb-SREBP 1a mice the insulin sensitivity
and ß-cell failure were significantly pronounced (Figure 11). So
also for these parameters the alb-SREBP-1aDP show values
intermediate to C57BL6 and alb-SREBP-1a mice.
Phosphorylation of SREBP-1a reduced serum cytokine
pattern
Wether obesity or ectopic hepatic lipid accumulation are
associated to inflammation is still under debate [22–24]. To
determine wether the lipid accumulation in liver and the vast
increase of adipose tissue un the alb-SREBP-1a mice affets
inflammatory parameters and wether the phosphorylation deficent
mutant has an impact on inflammation, a set of 40 chemokines
and cytokines was analyzed in serum of control and transgenic
animals (Figure 12). In C57Bl6 chemokines, i.e. C5a, sICAM,
CSF-1, CSF-2, MCP-1, INF-c, CCL-1, CCL-11, CXCL-1, Timp-
1 and Trem-1, but no proinflammatory cytokines could be
determined (Figure 12).
Figure 6. Liver specific overexpression of HA-SREBP-1aDP and HA-SREBP-1a in vivo. (A) Scheme of the DNA constructs used to generate
transgenic mice. The transcriptional active N-terminal domain of the phosphorylation mutant of the human SREBP-1a, SREBP-1aDP, or the human
SREBP-1a gene were inserted into a vector construct containing the mouse albumin promoter and a liver specific enhancer element next to a HA-Tag
and a polyadenylation site. Constructs only differ in three aminoacids, i.e. the MAPK phosphorylation sites S63, S117 and T426 that have been
mutated to S63A, S117A and T426V as indicated in the scheme. (B) Verification of transgene insertion into genomic DNA by PCR. M: marker, genomic
DNA of lane 1: C57Bl6, 2: alb-SREBP-1aDP, 4: C57Bl6, 5: alb-SREBP-1a, lane 3 and 6: no template controls. (C) Validation of transgene expression on
mRNA level by RT-PCR. RNA extracted from snapp frozen liver biopsies from male alb-SREBP-1aDP, alb-SREBP-1a or C57Bl6 mice were analyzed by RT-
PCR with transgene human HA-SREBP-1a, mouse SREBP-1a, mouse SREBP-1c and mouse SREBP-2 specific primers and probe. The relative RNA
amount shown in arbitrary units was calculated and plotted 6 SD. Graphs represent data from ten male mice per genotype, each analyzed in
triplicate (p,0.01). (D) Verification of transgene expression on protein level in liver. Protein extracts of snap frozen liver biopsies from lane 1: SREBP-
1aDP, 2: alb-SREBP-1a, and 3: C57Bl6 mice were separated by SDS-PAGE and blotted on nitrocellulose membrane. Membranes were probes with
SREBP-1 specific antibodies to determine SREBP-1 precursor protein (K10, SantaCruz) and total nuclear SREBP-1 (H160, SantaCruz) contend. To
determine the HA-tag of the transgene construct membrabes were probed with HA-specific antibody. For normalizing blots were probed with a-
tubulin antibody. A representative experiment is shown. (E) Graphs show densitometry evaluation for SREBP-1 precursor, nuclear SREBP-1 contend
and the transgenic HA-SREBP-1a construct of n=5 independent experiments with the levels determined for SREBP-1aDP set as 100%. Tissue specific
expression of alb-SREBP-1aDP( F) and alb-SREBP-1a (G). Protein extracts of lane 1: liver, 2: pancreas, 3: heart, 4: kidney, 5: small intestine and 6: skeletal
muscle, were separated by SDS-PAGE, blotted and probed with HA-specific antibody. A representative experiment is shown. The arrow indicates HA-
tagged SREBP-1a.
doi:10.1371/journal.pone.0032609.g006
Table 1. Gene expression of lipid metabolic genes in livers of
C57Bl6 and alb-SREBP-1c.
C57Bl6 alb-SREBP-1aDP alb-SREBP-1a
FAS 7.8863.14 37.49610.81
** 272.90694.05
**{{
SCD1 152.30678.34 302.76670,11
** 2145.726498.32
**{{
GPAT 0.7560.40 1.8860.81
** 11.9362.89
**{{
HMG-CoAR 1.2960.37 2.3960.37
** 18.9966.41
**{{
LDLR 0.3560.05 0.9060.32
** 2.0760.59
**{{
ABCA1 0.4460.03 1.1260.31
** 2.3360.61
**{{
MTTP 13.6565.03 18.7366.60 48.77615.66
**{{
PEPCK 4.0662.46 23.61610.02
** 61.03620.82
**{{
GLUT2 17.3963.41 21.1866.12 38.0366,5
**{{
pyruvate kinase 58.7568.05 54.30612.41 111.08634.81
**{{
malic enzyme 0.0160.002 0.0160.003 0.0260.001
**{{
The hepatic expression level of genes were determined by RT-PCR (n=20 each).
The relative RNA amount shown in arbitrary units was calculated and plotted 6
S.D. (C57Bl6 vs. alb-SREBP-1a or alb-SREBP-1aDP mice: **p,0.001; alb-SREBP-
1aDP vs. alb-SREBP-1a mice: {{p,0.001.)
doi:10.1371/journal.pone.0032609.t001
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of alb-SREBP-1a and alb-SREBP-1aDP mice, nevertheless the
abundance of some cytokines is altered. Again the alb-SREBP-
1aDP show a cytokine profile more comparable but not totally
identical to C57Bl6. An increase in CSF-2 and CXCL-1 and a
reduction in TREM-1 can be otained. In contrast, significant
alterations in the alb-SREBP-1a mice is the reduced abundance of
the respective chemokines exept for C5a and sICAM where no
alteration can be obtained.
Discussion
SREBP-1a has been identified as a connective link at the gene
regulatory level integrating signaling of various hormones,
cytokines, and metabolites [17]. Recruitment of MAPK cascades
is a general mechanism for a rapid gene regulatory answer of cells
to environmental stimuli by setting the activation state of different
transcription factors. JNK and p38 MAPKs target transcrip-
tion factors directly by phosphorylation thereby altering their
transactivity leading to changes of cellular gene regulatory
networks [21].
Here, we provide direct evidence that SREBP–1a is a selectively
phosphorylated target of JNK and p38 signaling cascades and
might link MAPK cascades to lipid metabolism.
MAPK cascades are the paradigm of activiation by sequential
phosphorylation with high target substrate specificity. Previously,
we have shown that the SREBP transcription factors are targets
for intracellular signaling pathways [16–20]. We could show that
SREBPs are substrates for ERK-MAPK and identified 432 and
455 as major phosphorylation in SREBP-2 and serine 117 in
SREBP-1a [16,19]. Here we demonstrate that serine 117 in
SREBP-1a is also the major phosphorylation for JNK site but does
not play a role for p38 MAPK signaling instead S63 and T426,
indicating selective phosphorylation of SREBP-1a by different
MAPK-families. JNK shares the major phosphorylation site S117
in SREBP1-a with ERK, a phenomenon which is also observed in
the regulation of other transcription factors [25–27]. On the other
hand differential targeting of transciption factors by MAPK is a
Figure 7. Weight gain and Food intake of C57Bl6, alb-SREBP-1aDP and alb-SREBP-1a transgenic animals. Male C57Bl6, alb-SREBP-1aDP
and alb-SREBP-1a mice (n=20 per genotype) were housed as groups of four under standard conditions with unlimited access to water and regular
chow (13.0 MJ/kg: 53% carbohydrates, 11% fat, 36% protein). Weight gain (A) and Food intake (B) were measured once a week starting at weaning
and monitored for an observation period of 18 weeks. Body weight (C), liver weight ((D) and WAT weight (E) were determined at sacrification. WAT
contend per body weight (F), food uptake per body weight and (G) weight gain per food uptake (H) were determined in each group of mice. Data
are given as means including standard deviation (6SD).
doi:10.1371/journal.pone.0032609.g007
Figure 8. Macroscopic and histological comparison of livers from C57Bl6, alb-SREBP-1aDP and alb-SREBP-1a mice. Male mice of each
genotype (C57Bl6, alb-SREBP1aDP, alb-SREBP-1a (n=20 per genotype)) were housed as groups of 4 under standard conditions with unlimited access
to water and regular chow (13.0 MJ/kg: 53% carbohydrates, 11% fat, 36% protein). (A) Livers of a C57Bl6 mouse (left), alb-SREBP-1aDP (middle) or alb-
SREBP-1a (right). All photographs were taken with the same magnification. (B) Liver tissue of the Lobus caudatus, Lobus sinister- and Lobus dexter
lateralis were fixed in 4% paraformaldehyd/PBS and embedded in paraffin with automated standard histological procedures. (I) Standard hematoxylin
and eosin staining was performed on 3 mm deparaffinized sections. (II) PAS staining was performed to determine glycogen contend. (III) The tissues
were also used for cryofixation and Oil-red-O staining was used for lipid visualization. (IV) Fibers and extra cellular matrix were visualized using the
‘‘van Gierson kit’’ to determine tissue integrity. The overview magnification is 1:10 and details are shown in 1:80 magnification.
doi:10.1371/journal.pone.0032609.g008
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transcription factor Elk-1, c-Myc, and nuclear receptors [25–27].
MAPK phosphorylation sites are designated by the consensus sites
S/TP [28], PXS/TP [29–31] or PXXS/TP [31]. The specificity
of the different members of the MAPK family and of the different
isoforms of p38 MAPK is provided by a docking motif usually
composed of three domains: the basic region, the LXL motif, and
the hydrophobic region [32]. The hydrophobic region seems to be
of particular importance for the determination of the substrate
specificity for p38 MAPK [33,34]. In the case of SREBP-1a one
can postulate that the S63 is the main phosphorylation site as
adjacent to the LXL motive (LSL: aa 33–36) a complete PXS/TP
motive, i.e. PASP (aa 61–64), is present whereas at position T426
the LXL motive (LSL: aa 385–387) is followed by an incomplete
S/TP motive, i.e. TP (aa 426–427), that might function as a
weaker phosphorylation target for p38. The identified phosphor-
ylation sites differ in their consensus sequence, i.e. the JNK-specific
site has the PXXSP motive, whereas the p38-specific sites are
PXSP for S63 and TP for T426. [31]. As many potential
substrates contain these motifs, it is important to provide further
specificity determinants to direct individual kinases towards the
correct target. Interaction with specific docking proteins and
specific recruitment of substrates via the docking domains of the
MAPK exists. These docking domains can enhance the efficiency
of phosphorylation, and to generate signaling specificity. This
modular signal transmission in the cell can be seen as the basis for
an economic utilization of signaling components to implement
cellular response to altered environmental conditions with limited
signaling molecules. In the case of SREBP-1a the activation of the
protein following different stimuli seems to be necessary as an
Figure 9. Macroscopic and comparison of C57Bl6, alb-SREBP-1aDP and alb-SREBP-1a mice. (A) Male C57Bl6, alb-SREBP1aDP and alb-SREBP-
1a (n=20 per genotype) were housed as groups of four under standard isocaloric conditions with unlimited access to water and regular chow (13.0 MJ/
kg: 53% carbohydrates, 11% fat, 36% protein). Panels show a ventral view of C57Bl6, alb-SREBP-1aDP and alb-SREBP1a mice. (B) For histological
overview standard hematoxylin and eosin staining was performed on 3 mm deparaffinized sections of WAT. All photographs are in same magnification.
doi:10.1371/journal.pone.0032609.g009
Table 2. Basal serum parameters at the state of scarification.
C57Bl6 alb-SREBP-1aDP alb-SREBP-1a
cholesterol [mg/dl] 104.62615.29 83.39614.09 93.47610.15
triglceride [mg/l] 121.10627.84 94.89624.42 235.27639.78
**{{
FFA serum [g/l] 0.8960.09 1.3960.14
** 2.5360.21
**{{
TFA liver [mg/g
tissue]
24.964.2 37.062.9
** 97.2611.9
**{{
blood glucose
[mmol/l]
7.7760.89 7.1660.77 10.9062.49
**
insulin [ng/ml] 0.9260.41 1.3661.32 4.0961.36
**
leptin [ng/ml] 15.8165.71 20.1168.05 44.3966.78
**
ALT [U/l] 34.05610.69 42.72617.15 55.67626.86
**
AST [U/l] 36.38616.58 46.61613.38 60.07618.67
**
Parameters were measured in C57Bl6, alb-SREBP1aDP and alb-SREBP-1a mice
housed as groups of 4 under standard conditions with unlimited access to
water and regular chow (13.0 MJ/kg: 53% carbohydrates, 11% fat, 36% protein)
at 24 weeks of age. Data are given as mean 6 SD (n=20). (**p,0.01: alb-SREBP-
1aDP or alb-SREBP-1a vs. C57Bl6; {{p,0.01: alb-SREBP-1aDP vs. alb-SREBP-1a).
doi:10.1371/journal.pone.0032609.t002
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response to altered nutrient composition, growth requirements or
cellular stress. So a preferential phosphorylation of distinct sites
depending on the cellular demands can be modified according to
the signal. Therefore phosphorylation of SREBP–1a appears to be
a regulatory step linking stress signals with metabolic events, i.e.
cellular lipid metabolism in the case of SREBP-1.
Phosphorylation of SREBP-1a might also affect other post-
translational modifications. The work of Sundqvist et al. [35]
showed that the amino acid T426 and the adjacent S430 in
mature SREBP-1a is involved in the ubiquitin-dependent protein
degradation and mutation to alanine of these sites increased
protein stability. This phosphorylation dependent degradation was
initiated by phosphorylation of mature SREBP-1a through the
protein kinase GSK-3. Up to now there is no evidence of
phosphorylation S63 and S117 in mature SREBP-1a on protein
stability. Yang and coworkers demonstrated that phosphorylation
of the transcription factor Elk-1 is not only differentially by various
MAPK cascades but activation is associated with a rapid loss of
SUMO modification [36]. This loss was related to increased
transcriptional activity. Interactions between phosphorylation and
SUMOylation have been described in SREBP-2 [37] and might
also interfere with transcriptional activation or protein stability.
Mutation of the phosphorylation site in SREBP-2 increases the
SUMOylation and therefore it was concluded, that hormone-
induced phosphorylation reduces SUMOylation [37]. This will
result in a complex regulative interplay. The SUMO sites K464 in
SREBP-2 is in direct proximity of the phosphorylation site S432
and S455, which we have identified previously [19]. In the case of
SREBP-1a, one of the SUMO sites, i.e. K123, is in close proximity
to S117. In addition K418 was identified as a further SUMO site
in SREBP-1a, but until today it had not been further investigated
because the adjacent phosphorylation site was unknown. In this
respect it is interesting to note, that the p38 site T426 is identical to
the the GSK-3 site and T430 appears to be in close proximity in
SREBP-1a, making an interaction likely. Different signalling
cascades can affect SREBP-1 phosphorylation and interfere with
the molecular function. For example the SREBP-1 isoform
SREBP-1c has recently been shown to be phosphorylated via
AMPK at S372 or SIK at S265, S266 and S325, respectively
[38,39] Although mechanisms involved do not directly increase
the transcriptional activity of the molecule but affect localization
and stability and there is no overlapp to the MAPK phosphor-
ylation sites identified in the present study, finally these
modifications also alter the gene expression rate of SREBP-1c
target genes. Further studies would have to explore the interaction
of these regulatory possibilities.
In general the N-terminal transcriptional active domain of
SREBP-1a has a basal transcriptional activity. In cell culture
experiments increasing the amount of SREBP-1a by overexpres-
sion is sufficient to induce transcription. This basal transcriptional
activation can be synergstically increased if there is a further
induction i.e. a hormonal stimulus to initiate the signalling
cascades to phosphorylation [15–17,20]. This phosphorylation
solely affects the N-terminal transcriptional active domain of
SREBP-1a, and not the precursor protein [15]. Mechanistically
the effect on increasing transcriptional activity by phosphorylation
gets obvious as the identified S63 and S117 are in the acid domain
Figure 11. Phosphorylation of SREBP-1a influences systemic insulin sensitivity. Surrogate indexes were calculated from fasting blood
glucose and plasma insulin concentrations as follows: QUICKI=1/(log(I0)+log(G0)), where I0 is fasting insulin (mU/ml) and G0 is fasting glucose
(mg/dl); and HOMA-IR=(G0 * I0)/22.5, with fasting glucose expressed as mmol/l and fasting insulin expressed as mU/ml. Data are given as box plot
analyses (n=20). ANOVA significance p,0.05 is indicated by an asterisks.
doi:10.1371/journal.pone.0032609.g011
Figure 10. Phosphorylation of SREBP-1a influences fatty acid composition of liver and serum. In liver tissues the composition total fatty
acid (TFA) (A) and in serum samples of the same animals the composition of free fatty acid (FFA) (B) of C57Bl6, alb-SREBP1aDP as well as alb-SREBP-1a
transgenic animals was determined by GC analyses. Data were calculated as percent of in TFA or FFA. The graphs indicate the percental difference the
values determined for alb-SREBP-1aDP and alb-SREBP-1a mice to C57Bl6 mice. Data are given as means including standard deviation (6SD) of (n=20)
replicates per genotype (*p,0.01: alb-SREBP-1aDP or alb-SREBP-1a vs. C57Bl6; {p,0.01: alb-SREBP-1aDP vs. alb-SREBP-1a).
doi:10.1371/journal.pone.0032609.g010
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Proteome Profiler
TM; R&D Systems, (Abingdon, UK). Spot intensities were normalized to background and positive controls set to 100% intensity.
Presented numbers on membranes mark targets as follows: (1) C5a; (2) CSF-3; (3) sICAM; (4) INF-c; (5) IL-12-p70; (6) CXCL-1; (7) CSF-1; (8) MCP-1;
(9) Timp-1; (10) Trem-1. Abundance of: CXCL13, CSF-2, CCL-1, CCL-11, IL1-a, IL1-ß, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-13, IL-16, IL-17, IL-23,
IL-27, CXCL-10, CXCL-11, MCP-5, CXCL-9, CCR-1a, CCL-4, CCL-2, CCL5, CXCL-12, CCL-17 or TNF-a was not detected in serum. (1) CSF-3; (2) GM-CSF
CSF-2; (3) CCL-1; (4) sICAM -; (5) IL-1ra; (6) IL-6; (7) CXCL-10; (8) CXCL-1; (9) CSF-1; (10) MCP-1; (11) CXCL-9; (12) MCP-5; (13) CCR-1a; (14) CXCL-2;
(15) CCL-5; (16) Timp-1. Abundance of: CXCL-13, C5a, CCL-11, IFN-c, IL1-a, IL1-ß, IL-2, IL-3, IL-4, IL-5, IL-7, IL-10, IL-13, IL-12-p70, IL-16, IL-17, IL-23, IL-27,
CXCL-11, CCL-4, CXCL-12, CCL-17, TNF-a or Trem-1 was not detected. Data are given as means 6 S.D. (n=6, each) of normalized intensity.
Significance was calculated by 2-way ANOVA. (C57Bl6 vs. alb-SREBP-1a or alb-SREBP-1aDP mice: *p,0.001; alb-SREBP-1aDP vs. alb-SREBP-1a
mice: {p,0.001.)
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cantly enhanced by adding further negative charges, i.e. phosphate
incorporation. The identified N-terminal phosphorylation sites
(S63, S117) are located in the acidic domain of SREBP-1a whereas
T426 is near the dimerization as well as the DNA binding bHLH-
LZ domain (amino acids 324–394) that exhibits the highest
sequence homology in the SREBP family. The position of the
latter phosphorylation site resembles the position of the phos-
phorylation sites for ERK-MAPK which we had identified
previously in SREBP-2 [19]. Deduced from the position,
phosphorylation of T426 in SREBP-1a might influence dimeriza-
tion or DNA binding. However, we show here that phosphory-
lation on these sites didn’t affect the bindinding of SREBP-1 to
both known core promoter elements, i.e. sre-1 or E-box. On the
other hand, transactivity of SREBP-1a is stimulated by phosphor-
ylation and hampered by the phosphorylation deficient mutants
accordingly.
The protein pool in the nuclear envelop seems to provide
sufficient mature SREBP–1a for posttranslational modification.
Previously we have shown that phosphorylation of SREBP-1a does
not interfere with mRNA expression, maturation or protein/DNA
interaction of SREBP-1a, but is related to ERK-MAPK pathway
inducible increase of e.g. gene expression of SREBP-1a target
genes like the LDLR and central genes of lipid metabolism in cell
culture models [20].
The limitation of cell culture models always is that they can’t
answer the question whether a mechanism identified has biological
importance and possibly allows the explanation of a pathophys-
iological process. To adress the potential biological importance of
SREBP-1a phosphorylation in vivo we have created mouse models
which express specifically in liver either the mature form of
SREBP–1aDP, which is deficient in all identified MAP kinase
phosphorylation sites, or the wild type SREBP–1a. Due to the
complex cholesterol dependant feedback regulation of SREBP–1a
secretion from membranes and the fact that cellular cholesterol
overload restrains the SCAP–SREBP–1 complexes to the
membranes, we overexpressed the transcriptional active N–
terminal domain directly, circumventing secondary effects due to
the complex and highly regulated releasing cascade of mature
SREBP–1a [14]. The key advantage of the utilization of the
albumin promoter in our system is that it turned out that the
animals develop a pathological phenotype already under normo-
caloric nutrition. There is no need of further physiological
provocation by feeding the animals a specific i.e. high fat diet to
induce a phenotype. This is of central importance as we intended
to monitor mainly the effect of SREBP-1a phosphorylation and
not the abundance of the molecule. The effect of the posttrans-
lational phosphorylation process otherwise might be masked
behind effects triggered by affluent food supply or specific food
components like increased transcription of the transgene that
might be induced in the PEPCK-SREBP-1a model [40]. Detailed
comparison of our animals shows that although both transgenic
models overexpress the transcriptional active N-terminal domain
of SREBP-1a in the liver to a comparable degree, overexpressing
of the functional SREBP-1a wild type shows a vast accumulation
of lipids in the liver including obesity and insulin resistance,
whereas the phosphorylation deficient alb–SREBP–1aDP mice is
protected. The hepatic gene expression of key SREBP-1a target
genes in the alb-SREBP-1a and alb-SREBP1aDP mice indicated
the functional overexpression of the respective molecules.
Overexpression of the N-terminal active domain of SREBP-1a
in mouse liver alters the regulation of SREBP-1a target genes. This
was comparable to the gene expresion alterations reported [40],
Compared to C57Bl6 the effect in the phosphorylation deficient
alb-SREBP-1aDP mice is a clear inducibility of gene expression
but the effect is by far not as pronounced as in the wildtype alb-
SREBP-1a mice. So the phosphorylation deficient mutant does not
act as a dominant negative manner but the synergistical
transcriptional activity induced by SREBP-1a overexpression
and phosphorylation is lost in these animals.
Clinical studies have shown that the intracellular amount of
lipid in liver is associated with insulin resistance. Therefore
syndromes like the non alcoholic fatty liver disease appears to be
a hepatic manifestation of insulin resistance or the metabolic
syndrome [41–43]. To further get insight to the physiological basis
of the observed phenotypes the status of insulin resistance and
insulin sensitivity of the animals was of interest. To get some
evidence it is feasible to use the surrogate indexes of insulin
resistance and sensitivity, i.e. HOMA-IR and QUICKI, developed
for humans which have sucessfully adopted to mice [44–47].
Altough blood glucose levels are unaffected in the alb-SREBP-
1aDP mice and only slightly elevated in alb-SREBP-1a
animals the indices in relation to insulin levels clearly show a
beginning of insulin resistance in SREBP-1a wild type mice
compared to phosphorylation deficient mice, which appears to
be primarily related to altered liver metabolism and the degree
of hepatic lipid accumulation. So all serum parameters indicate
that the alb-SREBP–1aDP mice are protected of the fatty
liver phenotype compared to the alb-SREBP–1a mice, which
develop fatty liver, obesity, hypertriglyeridemia, and insulin
resistance.
The pattern of circulating cytokines are a indicator for the
physiological condition of the liver. There is ongoing discussion of
the role of inflammation in the pathogenesis of obesity and fatty
[22–24] Neither alb-SREBP–1aDP mice nor alb-SREBP–1a
aminals show signs of increased secretion of cytokines involved
in the inflammatory systems. The alterations in the investigated
mice of serum cytokines affects mainly cytokines involved in
cellular regeneration and maintenance processes. This could
indicate that compensatory regeneration processes are active to
cope with the stress induced by the lipid accumlation in alb-
SREBP-1a mice. The missing indication of inflammation could be
a hint that at the present stadium of lipid accumulation in
hepatocytes the liver has not converted to a pathological condition
or promoting apoptosis, yet.
Taken together, we have shown that SREBP-1a is phos-
phorylated by JNK and p38 MAPK at different specific sites.
Furthermore, direct evidence is provided that phosphorylation
does not influence DNA binding but phosphorylation of the
identified sites plays a role in stress mediated effects on LDLR
promoter activity or activation and therefore affects target gene
expression. These data further support our concept that, besides
sterol-dependent cleavage, SREBPs are regulated by phos-
phorylation affecting their trans-activity by various MAPK
cascades leading to changes of cellular gene regulatory networks
[18–20].
Our investigations implicate that in liver phosphorylation of
SREBP-1a has biological implications on the development of fatty
liver and massive weight gain. This is impressively demonstrated
by the phosphorylation deficient SREBP-1aDP animals which are
are protected against all facets of the phenotype including lipid
accumulation, visceral adipositas and signs of persisting insulin
reristance. Phosphorylation of SREBP-1 also has clinical implica-
tions as we have recently reported a rare heterozygous mutation in
a patient with severe dyslipidemia hampering specifically phos-
phorylation of Erk- and JNK-MAPK specific S117 in SREBP-1a
[48]. These findings strongly support the biological relevance of
the posttranslational modification of SREBP–1a.
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Plasmid constructs
N-terminal domain of human sterol regulatory element binding
protein (SREBP)-1a was inserted in frame to glutathione-S-
transferase (GST) into pGEX 3X to generate SREBP-1a-NT
GST-fusion protein as previously described [16]. Generation of
SREBP-1a-NT S117A was described elsewhere [16]. The
construction of the mutated forms of SREBP-1a-NT (S63A,
S98A, T105V, T426V, S63A/T426V and S63A/S117A/T426V)
was produced by site-directed mutagenesis using the Quick
Change Mutagenesis Kit (Stratagene, Amsterdam, Netherland)
according to manufacturer’s recommendations. Expression vectors
containing SREBP-1a-NT were generated by cloning of corre-
sponding fragments from pGEX plasmids into pcDNA3.1/HisA
(Invitrogen, Karlsruhe, Germany). To construct Gal4-SREBP-1a-
NT, Gal4-SREBP-1a-NT S117A, Gal4-SREBP-1a-NT S63A/
T426V and Gal4-SREBP-1a-NT S63A/S117A/T426V the
corresponding fragments were ligated into expression vector pFA/
CMV (Stratagene) containing the DNA binding domain of yeast
transcription factor Gal4 (aa 1–147). Reporter plasmid pG5-luc
containing five Gal4 DNA binding sites cloned upstream of a
minimal promoter element and the firefly luciferase gene was
obtained from Promega (Mannheim, Germany). Expression vector
pFC/MEK3 for activated MKK3 (S189D/T193E; MKK3DE)
under control of CMV promoter was purchased from Stratagene.
The full length cDNA of MKK4 cloned in entry vector
(pDONOR201) was obtained from the RZPD consortium (Berlin,
Germany). The activated form of MKK4 (S292D/T296E;
MKK4DE) was generated by site directed mutagenesis and
subcloning into the destination vector pTRExDEST30 designed
as pTREx/MKK4DE using the Gateway cloning system
(Invitrogen, Darmstadt, Germany). The Renilla expression vector
pRL(-mcs) was generated by eliminating the multiple cloning site
of pRL null vector supplied from Promega. Construction of
expression vector containing HA tagged N-terminal domain of
human SREBP-1a-NT was described previously [49]. To generate
transgenic mice with liver specific overexpression, an expression
plasmid encoding HA-SREBP-1aDP (S63A, S117A, T426V) or
wild type HA-SREBP-1a was constructed. To assure tissue specific
expression in liver the expressing vector, based on pBlueskript II
KS (Stratagene), was generated by inserting 2kb of albumin
enhancer sequence corresponding to the NheI/BamHI enhancer
fragment [50] and the mouse albumin promoter (308 to +8)
containing all relevant transacting elements [51] into the BamHI
site. All necessary inserts were generated by PCR from C57Bl6
mouse genomic DNA. Subsequently a polyA cassette was inserted
via EcoRV/KpnI sites. HA-SREBP-1a-DP or HA-SREBP-1a was
cloned into this vector construct using the reconstituted BamHI/
EcoRV sites. The SREBP-1a expression cassette was released by
BssHI restriction, gel purified by using 0.7% agarose gel and
QIAquick gel extraction kit (Qiagen, Hilden Germany). The
sequences of all constructs were confirmed by sequence analyses
using a DNA sequencer model 3100 (Applied Biosystems,
Darmstadt, Germany).
Fusion protein production and protein kinase assay
GST-SREBP-1a-NT or mutated GST-SREBP-1a-NT (S63A,
S98A, T105V, S117A, T426V and S63A/T426V) fusion proteins
were by expressed in E. coli strain BL21-codon plus (DE3)-RP
(Stratagene) and purified according to the manufacturer’s
recommendations (GE Healthcare, Freiburg, Germany). Phos-
phorylation of 10 mg GST-SREBP-1a-NT fusion protein or 0.5 mg
PHAS by MAPK JNK1, JNK2, p38a, p38b and p38c (Upstate
Biotechnology, Heidelberg, Germany) were performed using
activated GST-JNK1, -JNK2, -p38a, -p38b or -p38c fusion
protein (40 ng/mg substrate) in kinase buffer (25 mM Tris/HCl,
pH 7.5, 6.25 mM ß-glycerophosphate, 1.25 mM EGTA,
0.25 mM sodium-orthovanadate, 1 mM DTT, 10 mM MgCl2).
The reaction was initiated by addition of 50 mM[ c
32P] ATP (10
Ci/mmol) in a final volume of 40 ml kinase buffer. The reaction
was terminated after 15 min at 30uC by addition of 56 SDS
loading buffer. The phosphorylated proteins were separated by
10% SDS-PAGE and analyzed by autoradiography of the
coomassie-stained dried gels.
For electro mobility shift assay 1 mg pcDNA3.1/HisA-SREBP-
1a-NT was in vitro transcribed and translated into His-tagged
protein by TNT T7/T3 coupled reticulocyte lysate system in a
final volume of 50 ml according to manufacturer’s recommenda-
tions (Promega). The His-tagged SREBP-1a-NT was purified
using Ni-NTA magnetic agarose beads (Qiagen). For phosphor-
ylation 200 ng of isolated protein was incubated with recombinant
activated JNK1 or p38a (40 ng/mg substrate) in kinase buffer
according to supplier’s instruction manual (Upstate Biotechno-
logy). To control for phosphorylation efficiency, kinase reaction
was performed with an aliquot of His-SREBP-1a-NT using
additionally 10 mCi [c
32P] ATP.
Peptide-map analyses by High Performance Liquid
Chromatography (HPLC)
10 mg of GST-SREBP-1a-NT or mutated GST-SREBP-1a-NT
fusion proteins phosphorylated by JNK1, JNK2, p38a, p38b or
p38c as described above were separated on a 10% SDS-PAGE
and phosphorylated proteins were in gel digested by trypsin
(Promega) over night. The peptides were eluted with 50 mM
ammoniumcarbonate and separated on an anion exchange
column (Nucleogel SAX 1000-8/46, 50 mm64.6 mm, Machery
& Nagel, Dueren, Germany) using Beckman gold solvent delivery
system (Beckman Coulter, Krefeld, Germany). The HPLC
flow rate was 0.5 ml/min. After injection of 1 ml sample the
peptides were eluted beginning at 100% buffer A (20 mM
NH4CH2COOH pH 7.0) and 0% of buffer B (0.5 M KH2PO4
pH 4.0). Ratios of B were increased to 10% in 40 min and from
10% to 50% in 75 min. Fractions of 0.5 ml were collected.
Cerenkov counting in scintillations counter (Beckman Coulter)
determined the relative amount of radiolabeled peptides.
Identification of p38 MAPK phosphorylation sites by
reversed phase HPLC and Matrix Assisted Laser
Desorption Ionization Mass Spectrometry
(MALDI-MS)
Reversed phase and MALDI-MS analyzes of GST-SREBP-1a-
NT fusion proteins phosphorylated by p38a (40 ng/mg substrate)
with 250 mM ATP (specific activity of 100 cpm/pmol; Cerenkov)
as described above were performed essentially as described [6,9].
In brief, proteins were separated by SDS-PAGE and phosphor-
ylated GST-SREBP-1a-NT was trypsin digested. Peptides were
subjected to reversed phase HPLC and further separated on C18-
reversed phase column. Fractions containing radiolabeled peptides
were subjected to Edman degradation and MALDI-TOF (time of
flight) mass spectrometry. Positive ion mass spectra were acquired
in a linear and reflector mode using an acceleration voltage of
20,000 V. In addition to manual interpretation of post source
decay (PSD) fragment ion spectra the SEQUEST
TM algorithm
was used to identify the peptide phosphorylation sites. For
database search the OWL sequence database (University of Leeds)
was used.
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Protein/DNA binding reaction was performed as described
with radiolabelled double-stranded oligonucleotide containing the
LDLR promoter consensus sre-1 fragment and ADD1/SREBP-1c
consensus E-box fragment [17,19]. The samples were separated on
native 5% (w/v) polyacrylamide gels. EMSA was analyzed by
autoradiography of the dried gel. Equal loading was confirmed by
western blot analysis of 20 ml protein mixture.
Dual Luciferase Reporter (DLR) gene assay
HepG2 cells (American Tissue Type Collection, HB-8065) were
maintained in standard medium (RPMI-1640, 10% (v/v) fetal calf
serum (FCS) and antibiotics (Invitrogen). Promoter reporter gene
analyses were performed as described [16,19]. Cell suspension
(2610
5 cells/well) was mixed with reporter plasmid pG5-luc
(0.5 mg/well), with pFA/Gal4-SREBP-1a-NT, pFA/Gal4-
SREBP-1a-NT S117A, pFA/Gal4-SREBP-1a-NT S63A/
T426V, pFA/Gal4-SREBP-1a-NT S63A/S117A/T426V or
pFA/CMV vector (25 ng/well), with pFC/MEK3, pTREx/
MKK4 or pFC vector (25 ng/well) and pRL(-mcs) (0.1 mg/well)
for control of transfection efficiency, respectively. Then plasmids
were transferred to an electroporation cuvette and electroporated.
Before seeding on six-well plates cell suspension was diluted with
standard medium. On day 1 after transfection cells were cultured
in lipid deficient medium (RPMI-1640) containing, 0.5% lipopro-
tein deficient serum (LPDS) (Sigma-Aldrich, Taufkirchen, Ger-
many)) for 16 h and treated as indicated below. Cell lyses and
measurements of firefly as well as renilla luciferase activities of cell
extracts (20 ml/probe) were performed according to supplier’s
instructions (Promega).
Preparation of cell extracts for western blot analyses
To detect precursor and nuclear SREBP-1 in liver and HA-
SREBP-1aDP or HA-SREBP-1a in liver and other tissues of the
transgenic animals at protein level, 10 mg of snap frozen tissue
samples (liver, pancreas, heart, small intestine, skeletal muscle)
were pottered (10 sec) in 250 ml hypotonic lysis buffer (10 mM
Hepes/KOH, pH 7.9, 20 mM KCl, 1.5 mM MgCl2, 0.5 mM
DTT, 1 mM EDTA, 1 mM EGTA) supplemented with protease
inhibitor cocktail (50 mg/ml ALLN, 0.5 mM PMSF, 10 mg/ml
leupeptin, 2 mg/ml aprotinin, 0.5 mM benzamidine) and phos-
phatase inhibitor cocktail (2 mM Na3VO4, 5 mM KF, 20 mM ß-
glycerophosphate). Samples were lysed by shearing 10 times
through a 25-gauge needle and centrifuged (2,0006 g, 10 min;
4uC). The resulting nuclear pellet was resuspended in hypertonic
buffer (20 mM Hepes/KOH, pH 7.9, 400 mM NaCl, 25 mM
KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 20% glycerol
(v/v)) supplemented with protease inhibitor cocktail and phospha-
tase inhibitor cocktail and incubated on a thermomixer (200 rpm,
30 min; 4uC). The extracts were centrifuged (20,0006g, 30 min;
4uC) and aliquots of supernatant, used as nuclear extract, were
frozen in liquid nitrogen and stored at 280uC. Protein extracts
were resolved on 7.5% SDS-PAGE and electroblotted to
nitrocellulose membrane (Hybond
TM ECL, GE Healthcare,
Munich, Germany) blocked and probed with mouse monoclonal
antibody against HA peptide (YPYDVPDYA) conjugated with
peroxidase (clone 3F10, 1:5000, Roche, Mannheim, Germany). A
polyclonal SREBP-1 antibody (K10, sc-367, 1:5000, SantaCruz)
was used to determine SREBP-1 precursor protein and the
polyclonal SREBP-1 antibody (H160, sc-8984, 1:5000, SantaCruz)
was used to determine the complete nuclear SREBP-1 contends.
Visualization was performed with ECL
TM plus western blotting
detection reagents according to manufacturer’s instructions (GE
Healthcare, Munich, Germany) and a Versa Doc instrument
(BioRad, Munich, Germany).
Generation of transgenic mice and genotyping
To generate transgenic animals approximately 450 fertilized
C57Bl6 oocytes were microinjected with alb-HA-SREBP-1aDPo r
alb-HA-SREBP-1a construct and placed into eight foster mice.
Of the offspring 5 founders were tested positive for the HA-
SREBP-1aDP and the HA-SREBP-1a construct, respectively.
To screen the presence of transgene ear biopsies were taken of
the animals at weaning and genomic DNA was extracted with a
tissue kit (Qiagen) according to manufactures instructions.
Routinely 50 ng DNA was used for PCR with albumin promo-
ter (59-ATGCGAGGTAAGTAT-39) and SREBP-1a-NT (59-
TAGGCCAGGGAACTGACTG-39) specific primers. The pres-
ence of the constructs was determined with a DNA 1000 kit on
2100 Bioanalyzer according to manufactures instructions (Agilent,
Boeblingen, Germany).
Animals, phenotypic and metabolic indices
C57Bl6, alb-SREBP-1aDP and alb-SREBP-1a mice were bred
and maintained in our animal facility in a regular 12 h light/dark
cycle under constant temperature and humidity (22uC61uC,
50%65% humidity). For environmental enrichment the cages
were supplemented with nesting material happi-matH (Scanbur
BK, Karlslunde, Denmark) and a mouse house (Techniplast,
Hohenpeißenberg, Germany). At the age of six weeks 12 male
littermates of each genotype were kept in colonies of four per
standard Macrolon III cage (Ebeco, Castrop-Rauxel, Germany).
Mice were fed ad libitum with standard laboratory diet (13.7 mJ/kg,
53% carbohydrate, 36% protein, 11% fat (Ssniff, Soest, Germany)
and they had free access to water. Weekly the animals were
controlled for weight gain; food or water intake was also
monitored. At the age of 24 weeks alb-SREBP-1aDP as well as
alb-SREBP-1a mice and age matched C57Bl6 mice were
sacrificed by CO2 asphyxiation. Mice of each genotype of the
German Diabetes Center colonies were also transferred to the
collaborating Institute for Diabetes Research to verify viability,
reproducibility and physiological as well as histological parameters
in an independent habitat. The Animal Care Committee of the
Universities of Duesseldorf and Hamburg approved animal care
and procedure (Approval#50.05-240-35/06 and #93/08).
Clinical parameters
Blood parameters were measured at 24 weeks of age. Blood
glucose was measured with Freestyle
TM (Abbott, Wiesbaden,
Germany) and triglycerides, cholesterol as well as liver enzymes
(ALT, AST) were determined on a Hitachie 912 laboratory
automat (Roche, Mannheim, Germany). Serum insulin levels
(mU/l) were measured in triplicate by ELISA according to the
manufactures recommendation (Mercodia, Uppsala, Sweden).
Fatty acid composition of serum or homogenate of liver biopsies
were determined on a Packard model 439 gas-liquid chromato-
graph equipped with a flame ionization detector and a 60 m
Hewlett-Packard fused silica capillary column as described [52].
Relative quantification of RNA by real-time PCR
Total RNA of 10 mg freshly isolated mouse liver biopsies was
extracted with RNeasy Mini Spin Kit (Qiagen). Real-time (RT)-
PCR was performed in triplicate with cDNA equivalent of 20 ng
reversed transcribed RNA (MMVRT, Promega) per reaction.
SREBP-1a and SREBP-1c isoform specific RT-PCR was
performed with the conserved probe according to [53] and
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The expression of HA-SREBP-1a and HA-SREBP-1aDP trans-
gene was confirmed with human specific primers and a primer
derived from the HA-tag sequence. Murine SREBP-2 and further
genes analyzed were detected with specific primers and probe
(Assay on Demand
TM, Applied Biosystems). RT-PCR was
performed under under standardized conditions (26 Universal
PCR Mastermix, Applied Biosystems) with an ABI Prism 7000
Sequence Detection System. Data were normalized to 18S RNA
content and relative RNA amount was determined according to
Fu et al. [55], with ((Egene)
2Ctgene/(E18S)
2Ct18S)*1,000,000 with
E=10
2(1/slope).
Histology
Tissues were resected and fixed in 4% paraformaldehyd/PBS
for 24 h and embedded in paraffin with automated standard
histological procedures (Excelsior
TM, Thermo Shandon GmbH,
Frankfurt, Germany). On 3 mm deparaffinized sections standard
hematoxylin and eosin (HE) staining was performed. Glycogen
storage was monitored with PAS staining (Merck, Darmstadt,
Germany). Fibers and extra cellular matrix were visualized using
the ‘‘van Gierson kit’’ (Merk, Darmstadt, Germany). For oil red O
staining, liver was resected and cryoprotected in 30% sucrose 4uC
over night. Thereafter tissue was frozen under liquid nitrogen
cooled isopentane and stored in liquid nitrogen until proceeding.
For cellular lipid detection, 3 mm sections of tissue were prepared
and stained with oil-red-O (Sigma). For characterization of cellular
histomorphology, fixed slips were stained in Mayer’s hemalaun
solution (Merck, Darmstadt, Germany) according to the manu-
facturer’s instructions.
Determination of the cytokine profile in serum and
adipocytes
For parallel detection of various cytokines, serum of C57Bl6,
alb-SREBP-1aDP and alb-SREBP-1a mice (n=6 each) were
hybridized to array membranes according to the protocol supplied
by the manufacturer (Proteome Profiler
TM; R&D Systems,
Abingdon, UK). Samples of each genotype were analyzed and
handeled in parallel troughout the entire procedure. Exposure,
data collection and processing of each set of arrays was also
performed in parallel (Versa Doc; BioRad). Spots were normalized
for internal hybridization positive controls after local background
substraction. Normalized data were analysed for genotype specific
differences as processed and results per set were used to determine
the mean differences in cytokine abundance.
Statistical analysis
Values are presented as means 6 SD. Statistical analysis
was performed Student T-test or by 2-way ANOVA calculated
with Prism 4.03 (GraphPad Software Inc., San Diego) as
indicated.
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